



SDI Review Form 1.6

Journal Name:	JournalofCancerandTumorInternational
Manuscript Number:	Ms_JCTI_19336
Title of the Manuscript:	Differential expression of Claudin-1, Claudin-3, and Claudin-4 in bladder lesions
Type of the Article	Original Research Article

GeneralguidelineforPeerReviewprocess:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lackofNovelty**', provided the manuscript is scientifically robust and technically sound.

To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<http://www.sciencedomain.org/page.php?id=sdi-general-editorial-policy#Peer-Review-Guideline>)



SDI Review Form 1.6

PART1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
<u>Compulsory</u> REVISION comments		
<u>Minor</u> REVISION comments	<p>The paper is a simple research article about an interesting subject with clinical interest but with a very confused objective. The authors studied the role of differential expression of Claudin-1, -3 and -4 in bladder lesions. They found that higher expression of Claudin-4 can be used as a molecular marker in follow up of low-grade and non-invasive lesions, as well as decreased expression of Claudin-1 and -3 in non-invasive lesions and invasive urothelial carcinomas is no conclusive. In my opinion, the correlation between Claudin-4 expression can be of clinical interest considering the therapeutic with clostridium perfringes enterotoxin. In the Introduction there are more recent data about the incidence of cancer. See 2012 statistics on Globocan. This should be included in the References</p> <p>References should reviewed. Some of them are not in accordance with recommendations of the Journal. English should be reviewed.</p>	<p>Thank you for your valuable comments. Actually we said in conclusion part decreased expression of Claudin-4 can show invasion capacity of the tumour and can be used for follow up. We added this data in the abstract part too. There are diverse results of Claudin 1 and Claudin 3 stainings in limited studies. We reported our results. This is not an end point. We emphasized the need of larger studies in the article.</p> <p>Recent data was taken from Globocon statistics and it was added to references.</p> <p>References was reviewed.</p> <p>English was reviewed.</p>
<u>Optional/General</u> comments		